High prevalence of metabolic syndrome and cardiovascular risk factors in men with ankylosing spondylitis on anti-TNFalpha treatment: correlation with disease activity

• Published in: Clinical and experimental rheumatology Vol. 27; no. 2; pp. 292 - 298
• Main Authors: Papadakis, J A, Sidiropoulos, P I, Karvounaris, S A, Vrentzos, G E, Spanakis, E K, Ganotakis, E S, Kritikos, H D, Mikhailidis, D P, Boumpas, D T
• Format: Journal Article
• Language: English
• Published: Italy 01.03.2009
• Subjects: Adult; Aged; Antibodies, Monoclonal - therapeutic use; Cardiovascular Diseases - complications; Cardiovascular Diseases - epidemiology; Case-Control Studies; Cholesterol, HDL - blood; Greece - epidemiology; Humans; Hyperlipidemias - complications; Hyperlipidemias - epidemiology; Hypertension - complications; Hypertension - epidemiology; Infliximab; Male; Metabolic Syndrome - complications; Metabolic Syndrome - epidemiology; Middle Aged; Prevalence; Risk Factors; Severity of Illness Index; Spondylitis, Ankylosing - complications; Spondylitis, Ankylosing - drug therapy; Spondylitis, Ankylosing - epidemiology; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Young Adult

Ankylosing spondylitis (AS) may be associated with an increased risk for cardiovascular diseases (CVD). We investigated the prevalence of cardiovascular risk factors and metabolic syndrome (MetS) in men with AS and assessed any correlation with AS-related factors. This was a cross-sectional study of...